KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) FCF Margin (2016 - 2025)

TherapeuticsMD's FCF Margin history spans 16 years, with the latest figure at 41.99% for Q4 2025.

  • For Q4 2025, FCF Margin rose 3944.0% year-over-year to 41.99%; the TTM value through Dec 2025 reached 81.2%, up 1476.0%, while the annual FY2025 figure was 81.2%, 1476.0% up from the prior year.
  • FCF Margin reached 41.99% in Q4 2025 per TXMD's latest filing, down from 127.42% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 5004.52% in Q3 2022 to a low of 11373.58% in Q3 2023.
  • Average FCF Margin over 5 years is 899.21%, with a median of 43.07% recorded in 2024.
  • Peak YoY movement for FCF Margin: plummeted -1637810bps in 2023, then soared 1136061bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 257.0% in 2021, then plummeted by -83bps to 44.1% in 2022, then tumbled by -2341bps to 988.05% in 2023, then soared by 100bps to 2.55% in 2024, then surged by 1548bps to 41.99% in 2025.
  • Per Business Quant, the three most recent readings for TXMD's FCF Margin are 41.99% (Q4 2025), 127.42% (Q3 2025), and 40.02% (Q2 2025).